The effect of systemic chemotherapy on hematological profiles in lung cancer patients

Amarudin Amarudin; Sri Melati Munir

doi:10.34011/jmp2k.v36i1.3610

Authors

Amarudin Amarudin Universitas Riau, Pekanbaru, Indonesia, Indonesia
Sri Melati Munir Universitas Riau, Pekanbaru, Indonesia, Indonesia

DOI:

https://doi.org/10.34011/jmp2k.v36i1.3610

Keywords:

chemotherapy toxicity, hematological changes, lung cancer

Abstract

Background: Cancer is a disease characterized by uncontrolled cell growth in one or both lungs originating from epithelial cells. In Indonesia, lung cancer ranks fourth among all cancer types and is the second leading cause of death after cardiovascular diseases. Management of lung cancer involves various therapeutic modalities, including surgery, radiotherapy, chemotherapy, and combination therapy. Certain chemotherapeutic agents, such as cisplatin and carboplatin, are known to have a narrow therapeutic index and high toxicity, so inappropriate regimen selection or dosing may result in serious adverse effects or even death. All chemotherapy agents carry the potential for toxicity, including both hematological and non-hematological effects, with hematological toxicities commonly manifesting as anemia, leukopenia, and thrombocytopenia of varying severity.

Objective: This study aimed to determine the hematologic profile in patients after chemotherapy.

Methods: This study was a descriptive research with a cross-sectional design using a total sampling technique. During the August-December 2023 period, 36 lung cancer patients met the inclusion criteria at Arifin Achmad Hospital, namely lung cancer patients with adenocarcinoma or squamous cell carcinoma who underwent advanced chemotherapy with a cycle of 21 days in the August-December 2023 period.

Results: Of the 36 patients, 29 (80.56%) were male. The highest age of patients undergoing chemotherapy was ≥ 40 years (94.44%). Changes in the hematological profile after chemotherapy occurred in 14 patients (38.89%), with the most common hematological profile being anemia.

Conclusion: The use of chemotherapy regimens can cause changes in the hematologic profile, including anemia, leukopenia, and thrombocytopenia.

References

[1] American Cancer Society, ‘Treating non-small cell lung cancer’, https://www.cancer.org/content/dam/CRC/PDF/Public/8706.00.pdf.

[2] WHO, ‘Lung cancer’, https://www.who.int/news-room/fact-sheets/detail/lung-cancer.

[3] National Cancer Institute, ‘SEER Cancer Stat Facts: Lung and Bronchus Cancer’, https://seer.cancer.gov/statfacts/html/lungb.html.

[4] N. H. Hanna et al., ‘Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update’, Journal of Clinical Oncology, vol. 38, no. 14, pp. 1608–1632, May 2020, doi: 10.1200/JCO.19.03022.

[5] Y. Yulindra, N. Hansen, E. Sabrina, S. Lilik, and A. Dian, ‘Hematologic Toxicities of Chemotherapy in Lung Cancer Patient: A Retrospective Study in DR. M. Djamil Hospital Padang, Indonesia’, Toksisitas Hematologis Akibat Kemoterapi pada Pasien Kanker Paru, vol. 8, 2019. doi: https://doi.org/10.15416/ijcp.2019.8.2.129

[6] P. Gargiulo et al., ‘Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials’, BMC Cancer, vol. 21, no. 1, p. 549, Dec. 2021, doi: 10.1186/s12885-021-08323-4.

[7] M. Raza and A. M. Gowda, ‘Platinum Hypersensitivity and Toxicity’, StatPearls https://www.ncbi.nlm.nih.gov/books/NBK617056/?utm.

[8] WHO, ‘Cancer control: Diagnosis and treatment’, https://www.who.int/publications-detail-redirect/cancer-control-diagnosis-and-treatment.

[9] Kemenkes RI, Panduan Penatalaksanaan Kanker Paru. Jakarta: Kemenkes RI, 2022.

[10] X. Guo et al., ‘Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer’, Lung Cancer, vol. 87, no. 2, pp. 162–168, Feb. 2015, doi: 10.1016/j.lungcan.2014.12.005.

[11] S. Neesanun, ‘Risk factors predicting chemotherapy-induced severe neutropenia and outcome in advanced stage non-small cell lung cancer: Data from the limited resource in Thailand’, Asian Pacific Journal of Cancer Care, vol. 7, no. 2, pp. 285–293, 2022.

[12] Y. Tolwin, R. Gillis, and N. Peled, ‘Gender and lung cancer—SEER-based analysis’, Ann Epidemiol, vol. 46, pp. 14–19, 2020, doi: 10.1016/j.annepidem.2020.05.008.

[13] H. C. Yang et al., ‘Age-Based Screening for Lung Cancer Surveillance in the US’, JAMA Netw Open, vol. 8, no. 11, p. e2546222, Nov. 2025, doi: 10.1001/jamanetworkopen.2025.46222.

[14] S. Salsabila, ‘Gambaran tipe sel kanker paru berdasarkan usia, jenis kelamin, dan paparan rokokdi RSUP Dr. M. Djamil Padang tahun 2018-2020’, JIKESI, vol. 4, no. 4, pp. 281–288, Dec. 2023.

[15] M. C. Rudy, I. A. Marhana, and D. Erawati, ‘Profil pasien kanker paru primer yang dirawat inap dan rawat jalan di RSUD Dr. Soetomo Surabaya’, Jurnal Respirasi, vol. 5, no. 3, pp. 65-71, 2019.

[16] W. Nie et al., ‘Obesity and survival in advanced non-small cell lung cancer patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy: a multicenter cohort study’, BMC Med, vol. 22, no. 1, p. 463, Oct. 2024, doi: 10.1186/s12916-024-03688-2.

[17] I. H. Ku and S. Ko, ‘Health-related characteristics of Cancer survivors according to body mass index: a secondary data analysis’, BMC Cancer, vol. 25, no. 1, p. 865, May 2025, doi: 10.1186/s12885-025-13871-0.

[18] Y. Zhang et al., ‘Global variations in lung cancer incidence by histological subtype in 2020: a population-based study’, Lancet Oncol, vol. 24, no. 11, pp. 1206–1218, Nov. 2023, doi: 10.1016/S1470-2045(23)00444-8.

[19] Md. R. Bin Sharif, A. M. M. S. Alam, H. M. N. Iqbal, S. B. A. Ayub, and M. Habibur Rahaman, ‘Comparative Efficacy and Cycle-Wise Toxicity of Paclitaxel-Carboplatin Versus Gemcitabine-Cisplatin in Stage IV Non-small Cell Lung Cancer (NSCLC): A Quasi-experimental Study in Bangladesh’, Cureus, Sep. 2025, doi: 10.7759/cureus.93093.

[20] M. Zhang, C. Xie, S. Liu, H. Fan, Z. Li, and X. Tong, ‘The Prognostic Value of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Lung Cancer: A Systematic Review and Meta-Analysis’, J Clin Med, vol. 14, no. 16, p. 5701, Aug. 2025, doi: 10.3390/jcm14165701.

[21] H. Kong et al., ‘Characteristics and risk factors for thrombocytopenia in malignancy patients with pulmonary embolism: a case control study’, BMC Pulm Med, vol. 25, no. 1, p. 483, Oct. 2025, doi: 10.1186/s12890-025-03946-w.

[22] A. Febriani and Y. Rahmawati, ‘Efek samping hematologi akibat kemoterapi dan tatalaksananya’, Jurnal Respirasi, vol. 5, no. 1, pp. 22-28, 2019.

[23] Aribowo and Sari, ‘Hematological side effects management of paclitaxel carboplatin chemotherapy in lung cancer’, Magna Medika: Berkala Ilmiah Kedokteran dan Kesehatan, vol. 10, no. 1, pp. 129–140, 2023.

[24] Y. Tolwin, R. Gillis, and N. Peled, ‘Gender and lung cancer—SEER-based analysis’, Ann Epidemiol, vol. 46, pp. 14–19, Jun. 2020, doi: 10.1016/j.annepidem.2020.04.003.

[25] Y. Sari and W. Aniwidyaningsih, ‘Perubahan Indeks Massa Tubuh, persentase otot rangka, dan kadar albumin pada pasien kanker paru KPKBSK sebelum dan setelah kemoterapi’, J Respir Indo, vol. 36 no. 2, pp. 73-82, April 2016

[26] D. Arumsari, K. D. Artanti, S. Martini, and S. Widati, ‘The description of smoking degree based on Brinkman Index in patients with lung cancer’, Jurnal Berkala Epidemiologi, vol. 7, no. 3, p. 249, Sep. 2019, doi: 10.20473/jbe.V7I32019.250-257.

[27] F. Ramadhaniah, D. Khairina, D. T. Sinulingga, E. Suzanna, and A. M. Jayusman, ‘Distribution of Lung Cancer Patients in Dharmais Cancer Hospital Year 2008-2012’, Jurnal Respirologi Indonesia, vol. 39, no. 1, pp. 31–36, Jan. 2019, doi: 10.36497/jri.v39i1.1.

[28] Noorwati Sutandyo and Eddy Suratman, ‘Non Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia’, Acta Med Indones, vol. 50, no. 4, pp. 291–298, 2018.

[29] N. Soetandyo, A. R. Hanafi, S. Agustini, and D. T. Sinulingga, ‘Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: adenocarcinoma <em>versus</em> squamous cell carcinoma’, Medical Journal of Indonesia, vol. 29, no. 1, pp. 26–31, Mar. 2020, doi: 10.13181/mji.oa.203787.

[30] J. Bohlius et al., ‘Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update’, Journal of Clinical Oncology, vol. 37, no. 15, pp. 1336–1351, May 2019, doi: 10.1200/JCO.18.02142.

[31] F. Casas, D. Muñoz-Guglielmetti, G. Oses, C. Cases, and M. Mollà, ‘Hematological Toxicity in Lung Cancer’, 2022, pp. 907–923. doi: 10.1007/174_2022_335.

[32] S. Wang et al., ‘Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis’, Eur J Clin Pharmacol, vol. 81, no. 4, pp. 479–493, Apr. 2025, doi: 10.1007/s00228-025-03803-z.